ZNTL compared with LPCN: revenue, margins and what each company keeps, and the suppliers and customers both name

ZNTLZentalis Pharmaceuticals, Inc.

Mkt capRevenueRevenue

LPCNLipocine Inc.

Mkt capRevenueRevenue

Compare

ZNTLZentalis Pharmaceuticals, Inc.

LPCNLipocine Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ZNTL1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.3%▼−15.60%×1.09

LPCN1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.95%—

= impliedZNTL realized, solidLPCN realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data

ZNTLZentalis Pharmaceuticals, Inc.

1.86▼−4.90%

Mkt cap$140.5MRevenue$27MQ4 FY24Revenue—

LPCNLipocine Inc.

1.43▼−0.85%

Regular sessionNov 2 '26

Mkt cap$11.9MRevenue$190,099Q2 FY26Revenue$2MFY25

Compare

Regular sessionNov 2 '26

ZNTLZentalis Pharmaceuticals, Inc.

LPCNLipocine Inc.

1.86▼−4.90%

Price

1.43▼−0.85%

$140.5M

Mkt cap

$11.9M

Q4 FY24$27M

Revenue

$190,099Q2 FY26

—

Revenue

$2MFY25

ZNTL1.86▼−4.90%vsLPCN1.43▼−0.85%Regular sessionNov 2 '26